Showing results (121-130 of 396) with videos related to

Sort By:
Pageof 40
Leukemia|March 1, 1994
New aspects on the pharmacokinetics of mitoxantrone and its two major metabolitesE Schleyer, A Kamischke, C C Kaufmann, et al.
Annals of Hematology|January 5, 2002
New insights into the biology of multiple myeloma using a combination of May-Grünwald-Giemsa staining and fluorescence in situ hybridization techniques at the single cell levelC Nickenig, N K Lang, C Schoch, et al.
MMW Fortschritte Der Medizin|August 3, 2007
[Elevated Hemoglobin--polyglobulia or polycythemia?]F Schneider, J Braess, M Feuring-Buske, et al.
Journal of Experimental Therapeutics & Oncology|September 1, 1996
Hexadecylphosphocholine inhibits phosphatidylinositol and phosphatidylcholine phospholipase C in human leukemia cellsD Berkovic, M Goeckenjan, S Lüders, et al.
Acta Haematologica|January 1, 1991
Further thoughts on 'cell kill' in acute leukemiaZ A Arlin, W Hiddemann, E Feldman, et al.
Biochemical Pharmacology|June 1, 1997
Differential regulation of phospholipase A2 in human leukemia cells by the etherphospholipid analogue hexadecylphosphocholineD Berkovic, S Lüders, M Goeckenjan, et al.
Leukemia|September 27, 2008
The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG)C Buske, E Hoster, M Dreyling, et al.
Onkologie|June 1, 1985
[AMSA/etoposide (VP 16-213). A phase I/II study in refractory acute myeloid leukemia]W Hiddemann, W Achterrath, D Urbanitz, et al.
European Journal of Medical Research|February 6, 2003
Elevation of soluble tumor necrosis factor receptor II in non-febrile patients with acute myeloid leukemiaM Goetz, X Schiel, H Heussel, et al.
Seminars in Oncology|December 1, 1990
Treatment of low-grade non-Hodgkin's lymphoma by cytoreductive chemotherapy with prednimustine/mitoxantrone followed by interferon alpha-2b maintenance: results of a clinical phase II studyW Hiddemann, M Unterhalt, P Koch, et al.
Pageof 40